DDD Partners LLC Acquires 108,941 Shares of Elanco Animal Health Incorporated $ELAN

DDD Partners LLC lifted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 6.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,753,369 shares of the company’s stock after purchasing an additional 108,941 shares during the period. Elanco Animal Health comprises approximately 2.2% of DDD Partners LLC’s holdings, making the stock its 5th biggest holding. DDD Partners LLC owned 0.35% of Elanco Animal Health worth $35,313,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Primecap Management Co. CA grew its holdings in Elanco Animal Health by 3.1% during the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after buying an additional 1,543,279 shares during the last quarter. Brandes Investment Partners LP lifted its position in shares of Elanco Animal Health by 11.3% in the second quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after acquiring an additional 820,901 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. Jennison Associates LLC increased its position in Elanco Animal Health by 322.0% during the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after purchasing an additional 2,468,122 shares in the last quarter. Finally, Holocene Advisors LP raised its stake in Elanco Animal Health by 29.1% in the 2nd quarter. Holocene Advisors LP now owns 2,886,294 shares of the company’s stock valued at $41,216,000 after purchasing an additional 649,820 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Morgan Stanley lifted their target price on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 18th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Finally, Barclays started coverage on Elanco Animal Health in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.44.

Elanco Animal Health Stock Up 1.5%

Shares of NYSE:ELAN opened at $25.15 on Friday. The company has a market capitalization of $12.50 billion, a price-to-earnings ratio of 419.30, a price-to-earnings-growth ratio of 3.71 and a beta of 1.87. The company has a 50 day moving average of $23.46 and a two-hundred day moving average of $21.01. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $26.08. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Insider Activity

In other Elanco Animal Health news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the purchase, the chief financial officer directly owned 124,233 shares in the company, valued at $2,688,402.12. This trade represents a 5.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence Erik Kurzius bought 10,000 shares of the business’s stock in a transaction on Friday, December 12th. The stock was acquired at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the transaction, the director owned 131,773 shares in the company, valued at $2,806,764.90. This represents a 8.21% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 43,450 shares of company stock valued at $937,883. Corporate insiders own 0.89% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.